Natalizumab

N/A

Report date: 2022/04/02 13:23:19
First In Class

Base Information

Drug NameNatalizumab
Drug Alias Name单抗那他珠Anti-alpha4 integrin monoclonal antibody那他珠单抗那他利珠单抗Tysabri +[13] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionIntegrin alpha-4/beta-7 antagonistsIntegrin alpha-4/beta-1 antagonists
TargetsIntegrin alpha-4/beta-1Integrin alpha-4/beta-7
Therapy Area/IndicationsIschemic StrokeGraft vs Host DiseaseDemyelinating Diseases +[11] 
Global Approved IndicationsMultiple Sclerosis, Relapsing-RemittingMultiple SclerosisCrohn Disease
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2004/11/23
Country/TerritoryCzechiaBelgiumCanada +[28] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBiogen IncPerrigo Llc
China Registration ClassN/A

Develop Information

Active CompaniesBiogen Netherlands BvBiogen IncQueen Mary University Of London +[5] 
Inactive CompaniesElan Pharma International LtdPhoenix Neurological Associates Ltd
Active IndicationsGraft vs Host DiseaseDemyelinating DiseasesMultiple Sclerosis, Relapsing-Remitting +[5] 
Inactive IndicationsIschemic StrokeEpilepsies, PartialMultiple Sclerosis, Chronic Progressive +[6] 

Other Information

ATC CodeL04AG03
Related LinksWikipediaDrugBankKEGG